TB preventive therapy preferences among children and adolescents

dc.contributor.authorStrauss, M.
dc.contributor.authorWademan, D.T.
dc.contributor.authorMcinziba, A.
dc.contributor.authorHoddinott, G.
dc.contributor.authorRafique, M.
dc.contributor.authorJola, L.N.
dc.contributor.authorStreicher, C.
dc.contributor.authorDu Preez, K.
dc.contributor.authorOsman, M.
dc.contributor.authorBoffa, J.
dc.contributor.authorHausler, Harry
dc.contributor.authorHesseling, A.C.
dc.contributor.authorHirsch-Moverman, Y.
dc.date.accessioned2024-08-06T12:44:07Z
dc.date.available2024-08-06T12:44:07Z
dc.date.issued2023-07
dc.description.abstractBACKGROUND : TB preventive therapy (TPT) is critical for ending TB, yet implementation remains poor. With new global guidelines expanding TPT eligibility and regimens, we aimed to understand TPT preferences among children, adolescents and caregivers. METHODS : We undertook a discrete choice experiment among 131 children, 170 adolescents and 173 caregivers, and conducted 17 in-depth interviews in 25 clinics in Cape Town, South Africa. The design included attributes for location, waiting time, treatment duration, dosing frequency, formulation/size, side effects, packaging and taste. Mixed-effects logistic regression models were used for analysis. RESULTS : Among children and caregivers, the number and size of pills, taste and side effects were important drivers of preferences. Among adolescents and caregivers, clinic waiting times and side effects were significant drivers of preferences. Adolescents expressed concerns about being stigmatised, and preferred services from local clinics to services delivered in the community. Dosing frequency and treatment duration were only significant drivers of choice among adolescents, and only if linked to fewer clinic visits. CONCLUSIONS : Introducing shorter TPT regimens in isolation without consideration of preferences and health services may not have the desired effect on uptake and completion. Developing TPT delivery models and formulations that align with preferences must be prioritised.en_US
dc.description.departmentFamily Medicineen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe Bill & Melinda Gates Foundation (Seattle, WA, USA) through their support of the South African National TB Think Tank; the Fogarty International Center of the National Institutes of Health (Bethesda, MD, USA); and the European Union.en_US
dc.description.urihttps://theunion.org/our-work/journals/ijtlden_US
dc.identifier.citationStrauss, M. Wademan, D.T., Mcinziba, A. et al. 2023, 'TB preventive therapy preferences among children and adolescents', International Journal of Tuberculosis and Lung Disease, vol. 27, no. 7, pp. 520-529. http://dx.DOI.org/10.5588/ijtld.22.0645.en_US
dc.identifier.issn1027-3719 (print)
dc.identifier.issn1815-7920 (online)
dc.identifier.other10.5588/ijtld.22.0645
dc.identifier.urihttp://hdl.handle.net/2263/97460
dc.language.isoenen_US
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen_US
dc.rights© 2023 The Union. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.en_US
dc.subjectDiscrete choice experimenten_US
dc.subjectPatient-centred careen_US
dc.subjectChildrenen_US
dc.subjectPreferencesen_US
dc.subjectTuberculosis preventive therapy (TPT)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleTB preventive therapy preferences among children and adolescentsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Strauss_TBPreventative_2023.pdf
Size:
652.08 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: